KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Change in Accured Expenses: 2009-2024

Historic Change in Accured Expenses for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $71.1 million.

  • Acadia Pharmaceuticals' Change in Accured Expenses rose 109.76% to $27.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.9 million, marking a year-over-year increase of 1.89%. This contributed to the annual value of $71.1 million for FY2024, which is 23.73% down from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Change in Accured Expenses stood at $71.1 million for FY2024, which was down 23.73% from $93.2 million recorded in FY2023.
  • In the past 5 years, Acadia Pharmaceuticals' Change in Accured Expenses registered a high of $93.2 million during FY2023, and its lowest value of -$8.5 million during FY2021.
  • For the 3-year period, Acadia Pharmaceuticals' Change in Accured Expenses averaged around $62.8 million, with its median value being $71.1 million (2024).
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first plummeted by 130.67% in 2021, then surged by 387.47% in 2022.
  • Acadia Pharmaceuticals' Change in Accured Expenses (Yearly) stood at $27.6 million in 2020, then tumbled by 130.67% to -$8.5 million in 2021, then spiked by 387.47% to $24.3 million in 2022, then skyrocketed by 283.32% to $93.2 million in 2023, then dropped by 23.73% to $71.1 million in 2024.